Search results for: Innovation Policy Prize
Filter search results
The Impact of New Medicines in the NHS: 70 Years of Innovation
1 August 2018
…role in determining the impact of new medicines. These themes highlight a variety of ways in which policymakers can facilitate positive impact from new medicines. Their role should be considered…
Payment Models for Multi-Indication Therapies
1 November 2021
…broad range of stakeholders to work toward consensus on the challenges and solutions which promote better patient access and sustainable health care and innovation. Traditionally, medicines are priced per pill…
Innovative Chemical Extensions: The Economic Basis of Pharmaceutical Progress
1 December 1988
…it to major ‘breakthrough’ innovations alone. That would seriously restrict the future benefits for patients, which, after all, is what pharmaceutical innovation must always have as its main objective. I…
Why Should Economic Evaluations of Medical Innovations Have a Societal Perspective?
1 October 2009
…cost benefit analysis to the payer perspective of cost-effectiveness analysis. Most voluntary and mandatory guidelines for evaluating medical innovation now encourage or require this narrower, budget-based payer perspective. As a…
OHE Authors Develop a Supply and Demand Model of Pharmaceutical Markets to Set Cost-Effectiveness Thresholds to Maximise and Distribute Social Welfare
15 June 2020
…investing in future medical innovations with the maximum possible patient access to currently available innovations. Maximising consumer (payer) surplus though, focuses only on maximising access in the present (static efficiency),…
Our Contributions to the Economics of Personalised Medicine
7 March 2018
…to improving the knowledge of both health care payers and the life sciences industry. This work promotes innovation by challenging the value of innovation, and facilitates decision making in order…
Health Financing and Pharmaceutical Policy Reform in the Countries of Central and Eastern Europe
12 January 1997
…care sector in the Countries of Central and Eastern Europe (CCEE). It shall assess the overall direction of the reforms and focus in particular on health financing and pharmaceutical policy…
“You Don’t Always Get What You Want”: Output Distortion and NHS Waiting Time Targets
18 December 2018
…that the policy worked to lower waiting times through a difference-in-difference approach comparing England (treatment) and Scotland (control) when the policy was first introduced. Generally, clear, measurable targets with hard…
Consolidation and Competition in the Pharmaceutical Industry
9 January 2001
…to provide specialised services to the large pharmaceutical companies. Empirical analyses of these trends highlight a series of important questions of particular interest to industrial economists and policy makers. What…